Skip to main
  1. Stocks
  2. Starling Oncology Inc
  3. Forecast
STLN

STLN Stock Forecast & Price Target

STLN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Starling Oncology is supported by a large, underpenetrated oncology market, with less than 1% penetration and demand tailwinds from rising cancer prevalence, utilization, and drug spend. Its 3Q26 results showed 24% revenue growth to $169.8M, adjusted EBITDA of $3.4M above expectations, and two consecutive quarters of positive EBITDA, while Specialty Pharmacy grew 44% and capitated revenue still rose 40% despite the Florida delay. The company’s differentiated care model, which has delivered 50%+ lower ED utilization and hospitalizations and $12,000+ in savings per enrolled patient, should support margin expansion as value-based contracts scale and the 2027 pipeline exceeds $1B.

Bears say

Starling Oncology is facing a negative fundamental setup because payer and physician preference could shift to other groups, limiting patient growth and expansion, while the company already lost a contract in 2024, raising the risk of further erosion. Its fairly heavy debt load constrains financial flexibility and may restrict investment in growth, even as the Dispensary business’ better margins are offset by reimbursement pressure in the pharmacy component. In addition, dependence on Medicare and Medicaid, capitation forecasting risk, and exposure to HHS, FDA, and CMS regulation create multiple operating headwinds that could pressure profitability and cash flow.

STLN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Starling Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

STLN Analyst Forecast & Price Prediction

Get the latest STLN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STLN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Starling Oncology Inc (STLN) Forecast

Analysts have given STLN a Strong Buy based on their latest research and market trends.

According to 4 analysts, STLN has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Starling Oncology Inc (STLN)


STLN Analyst Forecast & Price Prediction

Get the latest STLN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STLN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover STLN stock data and trends